The Therapeutic Goods
Administration has completed
a safety review of Coralan
(ivabradine) and as a result the
Product Information has been
updated to reduce the risk of
cardiovascular events in patients
taking the medicine for angina.
Coralan is a heart rate lowering
agent, and the changes to the PI
state that patients taking it for
angina must have a resting heart
rate above 70 beats per minute
(was 60bpm) before treatment.
Also, ivabradine should not
be taken in combination with
verapamil or diltiazem, while an
existing warning about a possible
interaction with grapefruit juice has
been strengthened.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Jul 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.